| Patent Number |
Title Of Patent |
Date Issued |
| 7097846 |
35 kD tumor associated protein antigen: uses and methods of detection |
August 29, 2006 |
| This invention provides the isolation and characterization of a tumor associated antigen which can be used for immunodiagnosis, immunoprognosis, and therapy of human cancer. The antigen is a protein molecule with a molecular weight of about 35 kD after reduction and separation by SDS |
| 6815170 |
Methods for lymph node identification |
November 9, 2004 |
| The present invention describes a method for identification of lymph nodes and the presence or absence of lymph node metastases as an important prognostic factor in early stage cancers of all types. A carbon black suspension is administered in combination with a second compound to a |
| 6491926 |
35 kD tumor associated protein antigen: uses and methods of detection |
December 10, 2002 |
| This invention provides the isolation and characterization of a tumor associated antigen which can be used for immunodiagnosis, immunoprognosis, and therapy of human cancer. The antigen is a protein molecule with a molecular weight of about 35 kD after reduction and separation by SDS |
| 6218166 |
Adjuvant incorporation into antigen carrying cells: compositions and methods |
April 17, 2001 |
| Disclosed are compositions and methods for enhancing the antibody and T cell response to cellular antigens by incorporating an immunopotentiating agent into the cellular membrane or into an intracellular compartment. Such adjuvant-incorporated cell compositions are useful in methods to |
| 6168787 |
Pluripotent vaccine against enveloped viruses |
January 2, 2001 |
| The present invention is directed to compositions and methods for the induction of immune responses in mammals against enveloped animal viruses. More particularly, the invention provides vaccine compositions containing multiple MHC allotypes. By generating an immune response against thes |
| 5993828 |
Tumor associated antigen compositions and methods |
November 30, 1999 |
| A method for inducing or enhancing in a human subject the production of antibodies reactive with the polypeptide subunit of Urinary Tumor Associated Antigen having a molecular weight of about 90 to 100 kD after reduction by .beta.-mercaptoethanol and separation by SDS-polyacrylamide |
| 5882654 |
Polyvalent melanoma vaccine |
March 16, 1999 |
| A new polyvalent melanoma cell vaccine is disclosed comprised of one or more allogeneic melanoma cell lines which contain effective concentrations of melanoma associated antigens. Further disclosed are a method of stimulating an immunological response by administering the described v |
| 5840317 |
Composition comprising tumor cell lines containing GD2 ganglioside GM2 ganglioside, M-TAA, and e |
November 24, 1998 |
| A new polyvalent melanoma cell vaccine is disclosed comprised of one or more allogeneic melanoma cell lines which contain effective concentrations of melanoma associated antigens. Further disclosed are a method of stimulating an immunological response by administering the described v |
| 5700649 |
Method of detection of urinary tumor associated antigen |
December 23, 1997 |
| The present invention describes Urinary Tumor Associated Antigen (UTAA), its isolation and use in diagnostic assays. In particular, UTAA has been identified in samples from cancer patients, in some cases as part of an immune complex of UTAA and UTAA-specific immunoglobulin. Isolated UTAA |
| 5102867 |
Therapeutic treatment of abnormal cell growth with follicle regulatory protein |
April 7, 1992 |
| A method of treating a patient exhibiting a neoplasm is provided comprising administering a therapeutically effective dose of Follicle Regulatory Protein (FRP), or a polypeptide analog thereof. The method may be used both pre- and post-operatively. |
| 4849402 |
Therapeutic treatment of abnormal cell growth with follicle regulatory protein |
July 18, 1989 |
| A method of treating patients exhibiting neoplasms of gonadal origin is provided comprising administering a therapeutically effective dose of Follicle Regulatory Protein (FRP). The method may be used both pre- and post-operatively. |
| 4557931 |
Antigenic compositions and methods for using same |
December 10, 1985 |
| GM2 is a ganglioside present on the surface of tumors and stimulates an appreciable immune response in mammals. It is useful when coupled with a non-toxic protein carrier or mixed with an adjuvent and injected parenterally of raising the anti-GM2 titer in serum. GM2 is also valuable |
